Logo image of ALLK

ALLAKOS INC (ALLK) Stock News

NASDAQ:ALLK - Nasdaq - US01671P1003 - Common Stock - Currency: USD

0.26  +0.01 (+2.85%)

After market: 0.255 -0.01 (-1.92%)

ALLK Latest News, Press Relases and Analysis

News Image
a month ago - Benzinga

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.

Mentions: BIIB RBLX CSCO ULCC ...

News Image
a month ago - Benzinga

Why Is Allakos Stock Plunging On Monday?

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 million in estimated costs.

News Image
7 months ago - BusinessInsider

ALLK Stock Earnings: Allakos Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the second quarter of 2024.Alla...

News Image
7 months ago - InvestorPlace

ALLK Stock Earnings: Allakos Beats EPS for Q2 2024

ALLK stock results show that Allakos beat analyst estimates for earnings per share the second quarter of 2024.

News Image
a month ago - Stocktwits

Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade

The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.

News Image
10 months ago - BusinessInsider

ALLK Stock Earnings: Allakos Meets EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allakos (NASDAQ:ALLK) just reported results for the first quarter of 2024.Allak...

News Image
10 months ago - InvestorPlace

ALLK Stock Earnings: Allakos Meets EPS for Q1 2024

ALLK stock results show that Allakos met analyst estimates for earnings per share the first quarter of 2024.

News Image
a month ago - Allakos Inc.

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore...

News Image
3 months ago - Kuehn Law, PLLC

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK)...

News Image
4 months ago - Allakos Inc.

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...

News Image
5 months ago - Allakos Inc.

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was...

News Image
7 months ago - Allakos Inc.

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...

News Image
9 months ago - Allakos Inc.

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects...

News Image
10 months ago - Allakos Inc.

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a...

News Image
10 months ago - Allakos Inc.

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the...

News Image
10 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday!

Mentions: HSDT VAXX LOCO ARDX ...

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!

Mentions: HUBC LGVN ALLR SNPO ...